Newron Pharmaceuticals S.p.A.

Fr 8.83As of Sun 8 Nov 2026, 12:00 UTC
SWX:NWRNHealthcare
Country Switzerland
PE (Fwd) •••
TSR 10Y CAGR (7.36%)
Div yield —
ROE —
Biotechnology
Beta (5Y) 0.84
PE TTM —
TSR TTM (38.85%)
Mkt cap Fr 187.5M
ROIC (81.54%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
Fr 8.90
0.83%
(86.77%)
Hold 5|2|11|5|7
4Q25
1Q26
2Q26
3Q26
Earnings per share€
0.10
0.11
0.11
0.12
29.96%
28.45%
13.72%
24.08%
Revenue€M
15.87
16.55
17.38
17.75
5.32%
12.57%
11.78%
15.88%
Peers (US$230.0M)
Cap (US$)
PE
955.8M
3.800x
22.58M
12.09x
230.0M
—
Capital
TTM
5Y
10Y
Leveragex
4.080
0.213
0.193
EBIT/Intx
3.299
0.214
0.196
Own earn%
(55.91)
(354.73)
(331.05)
Sh yield%
21.25
5.12
5.83
Owners
Insiders/Inst%
12.55
88.65
Short interest%
5.35
SBC / revenue%
5.23
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
0
Op margin range%
13–20
$1 testx
0.0
Incr. ROIC%
1